ライフサイエンスコーパス: zidovudine

1 ofovir, in 18% for stavudine, and in 10% for zidovudine.

2 cation with a superior resistance profile to zidovudine.

3 ceived single-dose nevirapine and 4 weeks of zidovudine.

4 Kenyan perinatal cohort receiving antenatal zidovudine.

5 All women were treated with antenatal zidovudine.

6 xyurea treatment or stopped prematurely with zidovudine.

7 of nevirapine plus 1 week of daily doses of zidovudine.

8 vir, lamivudine, zalcitabine, stavudine, and zidovudine.

9 to either nevirapine alone or nevirapine and zidovudine.

10 s support only the potential clinical use of zidovudine.

11 antiretroviral (ARV) combinations containing zidovudine.

12 Mice (C57Bl/6) were administered with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day)

13 In HIV-2, resistance to zidovudine (3'-azido-3'-deoxythymidine (AZT)) and other

14 so increases the sensitivity of the virus to zidovudine (3'-azido-3'-deoxythymidine; AZT).

15 All of the mothers received zidovudine 300 mg orally twice daily from 34 weeks' gest

16 tor regimen containing a lamivudine (150 mg)-zidovudine (300 mg) combination tablet (COM) and abacavi

17 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug

18 At week 96, patients receiving zidovudine/3TC had lost limb fat, and those receiving em

19 hers used prenatal ARV prophylaxis (prenatal zidovudine, 43.9%; HAART, 52.1%).

20 weeks) or in combination with lamuvidine and zidovudine (48 weeks).

21 r babies within 72 h of birth; regimen A) or zidovudine (600 mg orally at labour onset and 300 mg eve

22 with symptomatic KSHV-MCD received high-dose zidovudine (600 mg orally every 6 hours) and the oral pr

23 Mutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of i

24 mary damage to mitochondrial DNA, induced by zidovudine administration or homozygous mutation of mito

25 three NRTIs selected from an algorithm (eg, zidovudine after failure with tenofovir and vice versa;

26 A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance

27 n was significantly lower with ART than with zidovudine alone (0.5% in the combined ART groups vs. 1.

28 frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, P=0.004); preterm deli

29 as higher with tenofovir-based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03).

30 frequent with zidovudine-based ART than with zidovudine alone (20.5% vs. 13.1%, P<0.001).

31 y higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, P=0.008), and the rat

32 frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and was more

33 differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43).

34 y lower rates of early HIV transmission than zidovudine alone but a higher risk of adverse maternal a

35 wo- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV t

36 Antenatal ART included zidovudine alone in 23%; combinations without protease i

37 artum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir

38 r to those in cellular experiments that used zidovudine alone.

39 m transmission occurred in 24 infants in the zidovudine-alone group (4.8%; 95% confidence interval [C

40 (140 infants), with an increased rate in the zidovudine-alone group (P=0.03 for the comparisons with

41 e of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus thr

42 in the Americas and South Africa (566 in the zidovudine-alone group, 562 in the two-drug group, and 5

43 alogs (>1,000-fold increase in resistance to zidovudine and >250-fold to stavudine) but not to other

44 3% in 484 babies who received nevirapine and zidovudine and 20.9% in 468 babies who received nevirapi

45 rth, 34 (7.7%) babies who had nevirapine and zidovudine and 51 (12.1%) who received nevirapine only w

46 Analysis of these data suggests that zidovudine and d4T should not be prescribed in combinati

47 In contrast, the combination of zidovudine and gemcitabine was no more effective than ge

48 Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz pl

49 onfirmed the relative sensitivity of PERV to zidovudine and its resistance to all other RTIs.

50 g regimen containing efavirenz combined with zidovudine and lamivudine (but not efavirenz combined wi

51 (indinavir arm) to that of a combination of zidovudine and lamivudine (dual-nucleoside arm).

52 Starting with zidovudine and lamivudine combined with efavirenz (but n

53 lamivudine combined with efavirenz (but not zidovudine and lamivudine combined with nelfinavir) appe

54 regimens, starting with a regimen including zidovudine and lamivudine or a regimen including didanos

55 iteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved supe

56 d a randomized trial of initial therapy with zidovudine and lamivudine plus either nevirapine or rito

57 d in better outcomes than did treatment with zidovudine and lamivudine plus nevirapine.

58 sion, antiretroviral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinav

59 ricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz onc

60 tion with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two con

61 vir monotherapy, followed by the addition of zidovudine and lamivudine.

62 Estimated risks of HIV-1 transmission in the zidovudine and nevirapine groups were 10.3% and 8.1% at

63 ible to the reverse transcriptase inhibitors zidovudine and nevirapine.

64 ndow in which use of antiviral agents (i.e., zidovudine and raltegravir) may be of benefit.

65 nd gemcitabine) and antiviral drugs (such as zidovudine and ribavirin), have been shown to depend, at

66 birth demonstrated reduced susceptibility to zidovudine and ritonavir.

67 rical comparison group who received prenatal zidovudine and SD-NVP.

68 Women received zidovudine and single dose nevirapine for PMTCT and were

69 f at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week

70 ntiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmi

71 As tenofovir and abacavir have replaced zidovudine and stavudine in antiretroviral regimens, thy

72 nd enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible ef

73 e resistance with different implications for zidovudine and tenofovir cross-resistance, the primary c

74 -activated cytotoxic therapy using high-dose zidovudine and valganciclovir, can control symptoms and

75 received HAART (nevirapine, lamivudine, and zidovudine) and women who did not receive HAART.

76 04 (67%) children on stavudine, 103 (65%) on zidovudine, and 105 (64%), on abacavir (p=0.63; zidovudi

77 en were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir.

78 5 (81%) ART-naive children in the stavudine, zidovudine, and abacavir groups, respectively, had viral

79 nucleoside reverse-transcriptase inhibitors, zidovudine, and didanosine were not permitted.

80 was the main removal mechanism for abacavir, zidovudine, and emtricitabine, with half-lives (t1/2,pho

81 f treatment with a combination of indinavir, zidovudine, and lamivudine (indinavir arm) to that of a

82 illimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-trans

83 e triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to

84 ic procedure on three HIV drugs, (Indinavir, Zidovudine, and Nevirapine), discovered unique interacti

85 d for morphine, naloxone, buprenorphine, and zidovudine, and the results were confirmed by equilibriu

86 Zidovudine antiretroviral therapy did not confer a signi

87 IV-infected women and their infants received zidovudine as well as single-dose nevirapine or placebo.

88 enofovir disoproxil fumarate, amdoxovir, and zidovudine, as well as four natural endogenous dNTP.

89 in decline was steeper in patients receiving zidovudine (azidothymidine [AZT], -3.64 g/dL vs. no AZT,

90 4T) >> lamivudine (3TC) > tenofovir (PMPA) > zidovudine (AZT) > abacavir (metabolized to carbovir, CB

91 dine or emtricitabine): efavirenz (EFV) plus zidovudine (AZT) (n = 524); EFV plus tenofovir (TDF) (n

92 y (WBRT) and antiviral therapy consisting of zidovudine (AZT) and ganciclovir (GCV; MST 41.3 +/- 3.3

93 F77L), and all were found to be sensitive to zidovudine (AZT) and other drugs.

94 eoside reverse transcriptase (RT) inhibitors zidovudine (AZT) and tenofovir and the integrase inhibit

95 r CTNAs-acyclovir (ACV), cytarabine (Ara-C), zidovudine (AZT) and zalcitabine (ddC)-we show that TDP1

96 Stavudine (d4T) and zidovudine (AZT) are thymidine analogs widely used in th

97 to inhibit the incorporation and excision of zidovudine (AZT) by HIV-1 RT using DNA/DNA and RNA/DNA T

98 nd regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but d

99 ver, it has only recently been proposed that zidovudine (AZT) resistance can involve the excision of

100 monophosphate (AZTMP) in vitro and increases zidovudine (AZT) resistance in vivo.

101 We recently reported that zidovudine (AZT) selected for the Q509L mutation in the

102 AART drugs [ritonavir, indinavir, lopinavir, zidovudine (AZT), abacavir, stavudine, didanosine (ddI),

103 develop resistance to the nucleoside analog zidovudine (AZT), HIV-2 RT does not appear to use this p

104 The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and

105 ster of acyclovir, and the 5'-valyl ester of zidovudine (AZT), was purified from Caco-2 cells derived

106 nce testing was done for 220 HIV-1-infected, zidovudine (AZT)-exposed pregnant women and 24 of their

107 rent from either the wild-type (WT) T or the zidovudine (AZT)-selected T215Y/F.

108 han has previously been demonstrated between zidovudine (AZT)-triphosphate resistance data at the rev

109 to lamivudine and/or hypersusceptibility to zidovudine (AZT).

110 y defines such a mutagen, 3'-azidothymidine [zidovudine (AZT)], used widely in the treatment and prev

111 7-fold) and decreased hypersusceptibility to zidovudine (AZT; 1.4-2.2-fold).

112 ed ART was associated with higher rates than zidovudine-based ART of very preterm delivery before 34

113 ivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine alone (20.5% v

114 adverse events was significantly higher with zidovudine-based ART than with zidovudine alone (21.1% v

115 t of less than 2500 g was more frequent with zidovudine-based ART than with zidovudine alone (23.0% v

116 vudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and

117 highest among infants whose mothers received zidovudine-based ART.

118 m cells, from newborns exposed in utero to a zidovudine-based ARV combination present cytogenetic and

119 nterestingly the sEPD significantly improved zidovudine bioavailability by 100% as compared to oral

120 Zidovudine blocked formation of late viral replication p

121 hs of breastfeeding plus prophylactic infant zidovudine (breastfed plus zidovudine), or formula feedi

122 In multivariate analyses, patients on zidovudine-containing regimens had a greater reduction i

123 nodeficiency virus (HIV) is usually based on zidovudine-containing regimens, despite potential toxici

124 itor-based first-line regimen, followed by a zidovudine-containing, protease inhibitor (PI)-based sec

125 imens: single-dose nevirapine plus 1 week of zidovudine (control regimen) or the control regimen plus

126 Mutations selected during treatment with zidovudine, didanosine, and nevirapine differed among in

127 assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to re

128 viral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC

129 her, treatment with the antiretroviral agent zidovudine either significantly reduced or completely re

130 Lamivudine, zidovudine, emtricitabine, and tenofovir had no effects.

131 Lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir significantly i

132 were randomly assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopinavir/ritona

133 We evaluated zidovudine-experienced patients for whom treatment with

134 , lamivudine, and ritonavir was evaluated in zidovudine-experienced persons infected with human immun

135 s only the genetic variants, creatinine, and zidovudine exposure remained significant.

136 extended nevirapine) or with nevirapine plus zidovudine (extended dual prophylaxis) until the age of

137 om treatment with indinavir, lamivudine, and zidovudine failed, for indinavir-resistant minority vari

138 s, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks.

139 (HIV-1) infection to one of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovud

140 he first 8 days of life (two-drug group), or zidovudine for 6 weeks plus nelfinavir and lamivudine fo

141 vudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus three doses of nevirapine du

142 laxis with nevirapine or with nevirapine and zidovudine for the first 14 weeks of life significantly

143 ), or formula feeding plus 1 month of infant zidovudine (formula fed).

144 post-exposure prophylaxis of nevirapine plus zidovudine given to babies only reduced transmission of

145 ormula-fed group than for the breastfed plus zidovudine group (9.3% vs 4.9%; P = .003), but this diff

146 a single dose; babies in the nevirapine plus zidovudine group also received zidovudine twice daily fo

147 p) vs 9.0% (51 infants in the breastfed plus zidovudine group) (P = .04; 95% confidence interval for

148 (tenofovir group) or zidovudine-lamivudine (zidovudine group).

149 analysed in the stavudine group, 158 in the zidovudine group, and 164 in the abacavir group, and fol

150 tenofovir group and 4063 (73.2%) were in the zidovudine group.

151 no AZT, -2.08 g/dL), and patients receiving zidovudine had more anemia-related RBV dose reductions (

152 The genotoxicity of zidovudine has been established in experimental models.

153 drugs and HIV lipohypertrophy, stavudine and zidovudine have been implicated in the development of HI

154 high-level resistance to both lamivudine and zidovudine in HIV-2, and the combination of K65R, Q151M,

155 sdNVP), (2) WHO 2010 guidelines' "Option A" (zidovudine in pregnancy, infant nevirapine throughout br

156 oncentrations of nevirapine, lamivudine, and zidovudine in serum and whole breast milk from human imm

157 ble levels by using the antiretroviral drugs zidovudine, indinavir sulfate, and didanosine, demonstra

158 The peculiar mitochondrial pathology of zidovudine-induced mitochondrial DNA depletion, cytochro

159 ailable through the ministries of health and zidovudine is only sporadically available for prevention

160 ), but not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.2

161 dine, and nelfinavir (hazard ratio, 1.06) or zidovudine, lamivudine, and efavirenz (hazard ratio, 1.4

162 The combination of zidovudine, lamivudine, and efavirenz is superior to the

163 ating therapy with the three-drug regimen of zidovudine, lamivudine, and efavirenz is the optimal cho

164 The initial use of zidovudine, lamivudine, and efavirenz resulted in a shor

165 ompared the initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonav

166 jection of the HAART cocktail (consisting of zidovudine, lamivudine, and indinavir) to determine opti

167 patients who immediately began therapy with zidovudine, lamivudine, and indinavir.

168 ofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovud

169 ere randomized to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during p

170 dine, and efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.

171 eived the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.

172 231 [48.5%]; ARR, 1.31; 95% CI, 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 13

173 ine drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in z

174 at received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and th

175 ere associated with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir.

176 ing initial combination therapy of indinavir-zidovudine-lamivudine (ACTG 343 and Merck 035).

177 er cubic millimeter received nevirapine plus zidovudine-lamivudine (the observational group).

178 or [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) fro

179 icitabine or lamivudine (tenofovir group) or zidovudine-lamivudine (zidovudine group).

180 HIV RNA per milliliter than did those in the zidovudine-lamivudine group (84 percent vs. 73 percent,

181 At study week 12, 12% of patients in the zidovudine-lamivudine group had undetectable plasma HIV

182 More patients in the zidovudine-lamivudine group than in the tenofovir-emtric

183 udine twice daily plus efavirenz once daily (zidovudine-lamivudine group).

184 ir-emtricitabine group vs. 70 percent in the zidovudine-lamivudine group; 95 percent confidence inter

185 with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lam

186 dividuals to receive didanosine-stavudine or zidovudine-lamivudine, combined with efavirenz and/or ne

187 Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine o

188 r, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz.

189 l treatment of subjects infected with HIV-1: zidovudine-lamivudine-abacavir, zidovudine-lamivudine pl

190 ced lipid changes; all levels increased with zidovudine/lamivudine (3TC) and abacavir/3TC (except tri

191 were randomized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FT

192 se inhibitor pairs most frequently used were zidovudine/lamivudine (66% of PYFU), stavudine/lamivudin

193 zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial t

194 nd 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/

195 (monotherapy group, n = 69) or combined with zidovudine/lamivudine 300/150 mg twice daily (triple the

196 The antiretrovirals were zidovudine/lamivudine and nelfinavir or lopinavir/ritona

197 in utero tenofovir exposure; most were also zidovudine/lamivudine exposed.

198 Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs

199 vudine/abacavir (triple-nucleoside regimen), zidovudine/lamivudine plus EFV (3-drug EFV regimen) or z

200 Subjects (n=64) were randomized to receive zidovudine/lamivudine/abacavir (triple-nucleoside regime

201 amivudine plus efavirenz (3-drug regimen) vs zidovudine/lamivudine/abacavir plus efavirenz (4-drug re

202 /lamivudine plus EFV (3-drug EFV regimen) or zidovudine/lamivudine/abacavir plus EFV (4-drug EFV regi

203 ; P = .001) first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.

204 on treatment with indinavir, lamivudine, and zidovudine may occur slowly, depending on the genetic co

205 type was available, 4396 (50%) had received zidovudine monotherapy and 2949 (33%) combination ART.

206 ations of AIDS, despite having only received zidovudine monotherapy for a part of her life.

207 ldren receiving no antiretroviral therapy or zidovudine monotherapy only.

208 o therapy) and 9.6% during 1994-1996 (mostly zidovudine monotherapy) to 12.4% during 1997-1999 (dual-

209 1.32, 1.09-1.61), no ART (1.60, 1.32-1.94 vs zidovudine monotherapy), and antenatal combination ART (

210 5% CI 1.38-1.95), no ART (2.94, 2.43-3.57 vs zidovudine monotherapy), antenatal combination ART (1.40

211 ntenatal combination ART (1.40, 1.14-1.73 vs zidovudine monotherapy), WHO stage 4 HIV (2.42, 1.71-3.4

212 ntenatal combination ART (1.33, 1.12-1.60 vs zidovudine monotherapy).

213 On multivariate analysis, zidovudine monotherapy, a higher maternal viral load, an

214 associated with cARV therapy, compared with zidovudine monotherapy, with an adjusted odds ratio of 1

215 mother 200 mg; infant 2 mg/kg) and 7 days of zidovudine (mother 300 mg; infants 2 mg/kg) and lamivudi

216 Previous zidovudine or lamivudine use and presence at baseline of

217 n ritonavir-boosted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine

218 ophylactic infant zidovudine (breastfed plus zidovudine), or formula feeding plus 1 month of infant z

219 We aimed to compare stavudine, zidovudine, or abacavir as dual or triple fixed-dose-com

220 The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir.

221 ula fed) vs 86 infants (15.1% breastfed plus zidovudine) (P = .60; 95% confidence interval for differ

222 Patients receiving zidovudine plus d4T showed progressive declines in CD4 c

223 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtr

224 plus lopinavir and ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, o

225 f 3 intrapartum and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir

226 The main ART regimens included stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

227 ovir-disoproxil-fumarate plus emtricitabine, zidovudine plus lamivudine, or abacavir plus lamivudine)

228 ed comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitorin

229 These include interferon-alpha plus zidovudine (probably after 1-2 cycles of CHOP), intensiv

230 y of adding antiretroviral drugs to standard zidovudine prophylaxis in infants of mothers with human

231 Breastfeeding with zidovudine prophylaxis was not as effective as formula f

232 eeding (formula vs breastfeeding with infant zidovudine prophylaxis) interventions.

233 (FF) or breast-feed (BF) in combination with zidovudine prophylaxis.

234 s 123 ng/mL, but infants were also receiving zidovudine prophylaxis.

235 For abacavir and zidovudine, rapid transformation was attributable to hig

236 er stavudine failure in African populations, zidovudine rather than tenofovir may be preferred in sec

237 As expected, in the presence of zidovudine, recombinant viruses harboring the MNR RT fro

238 The nevirapine and zidovudine regimen is safe and easy to implement.

239 , 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.0%-3.1%) for the

240 a compared with a short intrapartum/neonatal zidovudine regimen.

241 In order to understand the impact of zidovudine resistance and thymidine analog mutations (TA

242 Polymorphism 172K significantly suppressed zidovudine resistance caused by excision (e.g. thymidine

243 udine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.

244 The zidovudine-resistant isolate exhibited low-level cross-r

245 hymidine analogue mutations had no effect on zidovudine sensitivity, the addition of Q151M together w

246 laxis with nevirapine or with nevirapine and zidovudine significantly reduces postnatal HIV-1 infecti

247 sed by the anti-HIV nucleoside drugs such as zidovudine, stavudine, and didanosine.

248 Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using

249 S for lamivudine or emtricitabine, abacavir, zidovudine, stavudine, didanosine, and tenofovir and a s

250 V mutation: susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increase

251 se transcriptase inhibitor (NRTI) backbones (zidovudine, stavudine, tenofovir, or abacavir, plus lami

252 Hence, the increased zidovudine susceptibility of RT(172K) results from its i

253 ied recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical i

254 years and anaemia was no more frequent with zidovudine than with the other drugs.

255 gimen (single-dose nevirapine plus 1 week of zidovudine); the control regimen plus nevirapine to age

256 o were treated with efavirenz and lamivudine/zidovudine; the planned treatment duration was 48 weeks.

257 alcohol use, metabolic/endocrine disorders, zidovudine therapy, and other infections.

258 ; or the control regimen plus nevirapine and zidovudine to age 14 weeks.

259 Using zidovudine to inhibit TK2, the synthesis of [(3)H]TTP fr

260 , or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-

261 respectively, phosphorylate ganciclovir and zidovudine to toxic moieties.

262 vides greater antiviral activity than d4T in zidovudine-treated patients.

263 with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 01

264 t isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and,

265 virapine plus zidovudine group also received zidovudine twice daily for 1 week (4 mg/kg weight).

266 g pregnancy and breastfeeding) or AZT/sdNVP (zidovudine until delivery with single-dose nevirapine wi

267 infection, demographic characteristics, and zidovudine use were not associated with the development

268 s, including age, nadir CD4(+) T-cell count, zidovudine use, and comorbid conditions.

269 ir, acyclovir, emtricitabine, lamivudine and zidovudine) via both bio- and phototransformation proces

270 ovudine, and 105 (64%), on abacavir (p=0.63; zidovudine vs stavudine: hazard ratio [HR] 0.99 [95% CI

271 the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.

272 and the median infant serum concentration of zidovudine was 123 ng/mL, but infants were also receivin

273 After 14 days of monotherapy, lamivudine/zidovudine was added to the VCV arms; subjects receiving

274 sure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated with increased r

275 udine, tenofovir, lamivudine, acyclovir, and zidovudine) was analyzed with three-dimensional ex vivo

276 troviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR,

277 One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly used combination

278 oncentrations of nevirapine, lamivudine, and zidovudine were 0.67, 3.34, and 3.21 times, respectively

279 ine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20-fold, 26-fold, 6-fold, 4-fol

280 Furthermore, low concentrations of TG and zidovudine were synergistic in inhibiting HIV replicatio

281 D4 cell count >250 cells/muL, most receiving zidovudine, were randomized at 28-38 weeks gestation to

282 B+ is not available, options A (short course zidovudine with single-dose nevirapine and an ARV "tail"

283 lpha, and 6 received consolidation high-dose zidovudine with valganciclovir.

284 of the T69del showed increased resistance to zidovudine, with little impact on other NRTI.

285 l load, CD4 cell count, and intention to use zidovudine, with the groups balanced by each site.

286 received SD-NVP, and some randomly received zidovudine (ZDV) as well.

287 Zidovudine (Zdv) is widely used to reduce maternal-infan

288 studies reported outcomes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP r

289 Intrapartum intravenous zidovudine (ZDV) prophylaxis is a long-standing componen

290 Resistance to zidovudine (ZDV) results from thymidine analog resistanc

291 Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-

292 tors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment

293 Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC)

294 850 (ACTG 850) evaluated the penetration of zidovudine (ZDV), lamivudine (3TC), and amprenavir (APV)

295 ected with HIV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritona

296 es in cardiac function have been reported in zidovudine (ZDV)-exposed uninfected children.

297 human immunodeficiency virus (HIV)-infected zidovudine (ZDV)-intolerant/refusing pregnant women and

298 toxicities of the 5 most common NRTI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI),

299 ed evaluable information on 2-drug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), an

300 etroviral therapy regimens (lamivudine [3TC]/zidovudine [ZDV]/efavirenz [EFV], 3TC/ZDV/nelfinavir [NF